GlassScriptPhysician profile
Barry Dicicco
NPI 1093717324
$5,097.47
in general payments reported to CMS, 2019-2025
24 companies · $208 in 2025
The $208 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $672 · 2020: $204 · 2021: $1,928 · 2022: $25.43 · 2023: $1,902 · 2024: $158 · 2025: $208.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,869 · Food and Beverage: $399.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,869.00 |
| Food and Beverage | $399.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $1,917.54 | 2021-2023 | Dupixent |
| Genentech, INC. | $1,000.00 | 2021 | |
| Glaxosmithkline, LLC. | $515.46 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $503.55 | 2019-2025 | Breztri, Fasenra, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $232.57 | 2019-2021 | |
| Mylan Specialty L.P. | $189.99 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $114.84 | 2019-2022 | |
| Genzyme Corporation | $109.20 | 2021-2025 | |
| Harmony Biosciences LLC | $75.62 | 2020-2021 | |
| Insmed, INC. | $50.42 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $49.02 | 2021 | |
| Exact Sciences Corporation | $41.82 | 2025 | Cologuard Collection Kit |
| Actelion Pharmaceuticals US, INC. | $41.33 | 2019-2021 | |
| Medtronic, INC. | $36.22 | 2024 | Closurefast |
| Axsome Therapeutics, INC. | $33.71 | 2024 | Sunosi |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $32.84 | 2021 | |
| Verona Pharma, INC. | $29.43 | 2025 | Ohtuvayre |
| Fisher & Paykel Healthcare INC | $24.83 | 2019 | |
| Genentech USA, INC. | $24.16 | 2021 | |
| Merck Sharp & Dohme LLC | $19.32 | 2024 | Vaxneuvance, Capvaxive |
| Circassia INC. | $17.42 | 2019 | |
| Advanced Respiratory, INC | $13.73 | 2021 | |
| Amgen INC. | $13.21 | 2024 | Tezspire |
| Electromed, INC. | $11.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barry Dicicco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.